These findings suggested that the A-485 function the antileukemia effects through inhibiting the CDK4/RB/E2F pathway, but independent of the classical MLL-HOXA9 signaling pathway in MLL-r AML. The gene discussed is RB1; the disease is acute myeloid leukemia.